US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by G1 Therapeutics
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
September 18, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
September 05, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
July 25, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
June 24, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
May 28, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
May 23, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
May 22, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
May 01, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
May 01, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
February 28, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
February 12, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
December 05, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
November 29, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
November 01, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
October 27, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
October 18, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
October 16, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
August 02, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
July 31, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
June 04, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
May 16, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
May 10, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
May 03, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 01, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
February 13, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
January 09, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
December 07, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
G1 Therapeutics Announces Closing of Offering of Common Stock
November 22, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Tickers
GTHX
